138 related articles for article (PubMed ID: 11585744)
1. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
Moffatt KA; Johannes WU; Hedlund TE; Miller GJ
Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744
[TBL] [Abstract][Full Text] [Related]
2. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
3. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines.
Sugibayashi R; Kiguchi Y; Shimizu T; Suzuki T; Hamada H; Takeda K
Anticancer Res; 2002; 22(2A):713-9. PubMed ID: 12014641
[TBL] [Abstract][Full Text] [Related]
6. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
Shiohara M; Uskokovic M; Hisatake J; Hisatake Y; Koike K; Komiyama A; Koeffler HP
Cancer Res; 2001 Apr; 61(8):3361-8. PubMed ID: 11309293
[TBL] [Abstract][Full Text] [Related]
7. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
Golovko O; Nazarova N; Tuohimaa P
Life Sci; 2005 Jun; 77(5):562-77. PubMed ID: 15904673
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
Bauer JA; Thompson TA; Church DR; Ariazi EA; Wilding G
Prostate; 2003 May; 55(3):159-67. PubMed ID: 12692781
[TBL] [Abstract][Full Text] [Related]
11. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.
Moffatt KA; Johannes WU; Miller GJ
Clin Cancer Res; 1999 Mar; 5(3):695-703. PubMed ID: 10100724
[TBL] [Abstract][Full Text] [Related]
12. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
13. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
14. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines.
Venkateswaran V; Klotz LH; Fleshner NE
Cancer Res; 2002 May; 62(9):2540-5. PubMed ID: 11980647
[TBL] [Abstract][Full Text] [Related]
15. 1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression.
Clark CS; Konyer JE; Meckling KA
Exp Cell Res; 2004 Mar; 294(1):301-11. PubMed ID: 14980523
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31.
Hedlund TE; Moffatt KA; Miller GJ
J Steroid Biochem Mol Biol; 1996 Jun; 58(3):277-88. PubMed ID: 8836163
[TBL] [Abstract][Full Text] [Related]
17. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells.
Stewart LV; Weigel NL
Prostate; 2005 Jun; 64(1):9-19. PubMed ID: 15651061
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
19. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
